Randomized trial · people

Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large 68-week trial, pairing cagrilintide with semaglutide led to 20.4% average weight loss versus 3.0% on placebo, with gut side effects common but mostly mild to moderate.

Kind
Randomized trial
Studied in
People
Number studied
3417
Published
2025
Journal
N Engl J Med

What they tested

The team tested whether giving cagrilintide and semaglutide together lowers body weight more than placebo over 68 weeks in adults with overweight or obesity.

How the study was done

A phase 3a, double-blind, randomized trial controlled with placebo (a dummy treatment) and with each drug alone, run over 68 weeks at many centers in 3417 adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. People were split 21:3:3:7 into the combination (2.4 mg of each drug), semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, and every group also got lifestyle support.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 68 weeks, body weight changed by an estimated -20.4% on the combination and -3.0% on placebo, a difference of -17.3 percentage points (95% confidence interval, -18.1 to -16.6). Compared with placebo, a larger share of people on the combination hit each weight-loss goal the trial tracked: losing at least 5%, at least 20%, at least 25%, and at least 30% of their starting weight (P<0.001 for each). Stomach and gut side effects, including nausea, vomiting, diarrhea, constipation or belly pain, affected 79.6% on the combination and 39.9% on placebo, and most were short-lived and mild to moderate.

What it doesn’t show

The main comparisons were made against placebo, not against either drug alone, and the trial only enrolled adults without diabetes over 68 weeks. It was funded by Novo Nordisk.

The paper

Garvey et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.

The compounds

More studies on Cagrilintide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cagrilintide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo